Company news
Cheng Du Sheng Nuo Biotec Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Completion of U.S. FDA Filing for Ziconotide Acetate API
October 29, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Report for Q3 2026
October 27, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on the Interim Profit Distribution Plan for 2026
October 27, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Terlipressin Injection
October 16, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Written Confirmation for Active Substances Exported to EU by Wholly-owned Subsidiary
October 13, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Receipt of Indictment by the Wholly-owned Subsidiary and the Actual Controller
October 9, 2026
(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Progress of Shareholding Increase by Senior Executive
October 8, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Obtaining the Drug Manufacturing License for New API Varieties and Passing the GMP Compliance Inspection
September 29, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Progress of Shareholding Increase by Senior Management
September 8, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Linaclotide Capsules
September 3, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for the Marketing Application of Terlipressin Acetate API
August 28, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Semi-annual Report for 2026
August 19, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Convening the 2026 Semi-annual Performance Briefing
August 17, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on the Initial Grant of Restricted Shares to Participants
July 23, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on the Results of Shareholding Increase by the Controlling Shareholder and the Change in Shareholder Equity Reaching the 1% Threshold
July 21, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
July 17, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
July 12, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 10, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Resolutions of the 3rd Meeting of the 5th Board of Directors
July 7, 2026
CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on the Controlling Shareholder's Shareholding Increase Plan
July 3, 2026
Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Peligacaran Drug Substance
June 25, 2026
Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Oxytocin Drug Substance
June 18, 2026
Announcement on Share Increase Plan for Senior Management Members
June 8, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 31, 2026
Announcement on Voluntary Disclosure of Completion of U.S. FDA Filing for Terlipressin Acetate Substance
May 21, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 12, 2026
Announcement on Voluntary Disclosure of Completion of U.S. FDA Filing for Tirzepatide Drug Substance
May 11, 2026
Announcement on 2025 Profit Distribution and Capital Reserve Conversion to Share Capital Plan and Interim Dividend Plan for 2026
April 23, 2026
Announcement on Voluntary Disclosure of Obtaining Drug Production License by Wholly-owned Subsidiary
March 30, 2026
Announcement on Shareholding Reduction Result and Non-Execution of Shareholding Reduction by Some Directors and Senior Management Members
March 22, 2026
Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Liraglutide Drug Substance
March 4, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of Proposed Selection Results of Participating in National Organized Bulk Purchasing of Drugs for Successive Procurements
February 11, 2026
Earnings Preannouncement for 2025
January 15, 2026
Announcement on Progress in Major Daily Operation Contracts of Wholly-owned Subsidiary
December 30, 2025
Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
December 17, 2025
Announcement on Shareholding Reduction Results for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members
December 14, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares to Below 5% and Reaching 1% Scale
December 10, 2025
Announcement on Voluntary Disclosure of Pentapeptide-18 Passing the New Cosmetic Ingredient Registration
December 3, 2025
Announcement on Election of Board of Directors at Expiry of Term of Office
December 1, 2025
Announcement on Shareholding Reduction Plan of Partial Directors and Senior Management Members
November 30, 2025
Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Vepnadeptide Drug Substance
November 19, 2025
Announcement on Implementation of Interim Dividend Distribution for 2025
November 10, 2025
Announcement on Making Provisions for Asset Impairment for the First Three Quarters of 2025
October 27, 2025
Indicative Announcement on Shareholder Terminating Concerted Action Relationship and Equity Change Reaching 1% Scale
October 14, 2025
Announcement on Voluntary Disclosure of Earnings Preannouncement for the First Three Quarters of 2025
October 13, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
September 17, 2025
Announcement on Shareholding Reduction Plan for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members
August 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 21, 2025